Evidence map›Paper›PMID 27470509›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2016

Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.

Hong Lu, Deborah A Howatt, Anju Balakrishnan, Mark J Graham, Adam E Mullick, Alan Daugherty

Registry-linked trialOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05310968 (Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction), which is not on this map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05310968 phase4completednot on this mapstarted 2022, after this paper: background citation

Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY)

TypeinterventionalSponsorBeijing Tiantan HospitalRan2022 to 2025Enrolled970ConditionsBranch Atheromatous DiseaseArmsTirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hong LuFrom the Department of Physiology (H.L., A.D.), Saha Cardiovascular Research Center (H.L., D.A.H., A.B., A.D.), University of Kentucky, Lexington; and Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA (M.J.G., A.E.M.). Hong.Lu@uky.edu Alan.Daugherty@uky.edu.
Deborah A HowattFrom the Department of Physiology (H.L., A.D.), Saha Cardiovascular Research Center (H.L., D.A.H., A.B., A.D.), University of Kentucky, Lexington; and Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA (M.J.G., A.E.M.).
Anju BalakrishnanFrom the Department of Physiology (H.L., A.D.), Saha Cardiovascular Research Center (H.L., D.A.H., A.B., A.D.), University of Kentucky, Lexington; and Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA (M.J.G., A.E.M.).
Mark J GrahamFrom the Department of Physiology (H.L., A.D.), Saha Cardiovascular Research Center (H.L., D.A.H., A.B., A.D.), University of Kentucky, Lexington; and Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA (M.J.G., A.E.M.).
Adam E MullickFrom the Department of Physiology (H.L., A.D.), Saha Cardiovascular Research Center (H.L., D.A.H., A.B., A.D.), University of Kentucky, Lexington; and Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA (M.J.G., A.E.M.).
Alan DaughertyFrom the Department of Physiology (H.L., A.D.), Saha Cardiovascular Research Center (H.L., D.A.H., A.B., A.D.), University of Kentucky, Lexington; and Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA (M.J.G., A.E.M.). Hong.Lu@uky.edu Alan.Daugherty@uky.edu.
Ionis Pharmaceuticals (United States) · US

Funding

Adventitial-medial interactions in thoracic aortic diseasesR01HL133723 · NHLBI · UNIVERSITY OF KENTUCKY · PI DAUGHERTY, ALAN · 2016 to 2019
$2.9M
NHLBI NIH HHS R01 HL133723
6 · The paper itself

Abstract

objectiveGain-of-function mutations of PCSK9 (proprotein convertase subtilisin/kexin type 9) lead to hypercholesterolemia. This study was to determine whether infection of normocholesterolemic mice with an adeno-associated viral (AAV) vector expressing a gain-of-function mutation of mouse PCSK9 increased angiotensin II (AngII)-induced abdominal aortic aneurysms. APPROACH AND

resultsIn an initial study, male C57BL/6 mice were injected intraperitoneally with either an empty vector or PCSK9 gain-of-function mutation (D377Y). AAV at 3 doses and fed a saturated fat-enriched diet for 6 weeks. Two weeks after AAV injection, mice were infused with AngII for 4 weeks. Plasma PCSK9 concentrations were increased dose dependently in mice injected with AAV containing PCSK9D377Y mutation and positively associated with elevations of plasma cholesterol concentrations. Infection with intermediate and high doses of PCSK9D377Y.AAV led to equivalent increases of maximal width of abdominal aortas in C57BL/6 mice infused with AngII. Therefore, the intermediate dose was used in subsequent experiments. We then determined effects of PCSK9D377Y.AAV infection on 5 normolipidemic mouse strains, demonstrating that C57BL/6 mice were the most susceptible to this AAV infection. PCSK9D377Y.AAV infected male C57BL/6 mice were also compared with age-matched male low-density lipoprotein receptor(-/-) mice. Although plasma cholesterol concentrations were lower in mice infected with PCSK9D377Y.AAV, these mice had equivalent abdominal aortic aneurysmal formation, compared to low-density lipoprotein receptor(-/-) mice. In a separate study, reduced plasma PCSK9 concentrations by PCSK9 antisense oligonucleotides in male low-density lipoprotein receptor(-/-) mice did not influence AngII-induced abdominal aortic aneurysms.

conclusionAAV-mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with AngII.

Indexed as

Angiotensin IIMutationAnimalsAortic Aneurysm, AbdominalBiomarkersCholesterolDependovirusDisease Models, AnimalGenetic Predisposition to DiseaseGenetic VectorsGene Transfer TechniquesHypercholesterolemiaMaleMice, 129 StrainMice, Inbred BALB CMice, Inbred C57BLAngiotensin IIBiomarkersCholesterolOligonucleotides, AntisensePcsk9 protein, mouseProprotein Convertase 9Receptors, LDLaortic aneurysmsatherosclerosishypercholesterolemialow-density lipoproteinPcsk9 protein, mouse

Identifiers

PMID27470509
PMCPMC5001883
OpenAlexW2504280184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.